Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

Yoshihisa Kitamura; Kouhei Kitagawa; Shizue Kimoto; Hidenori Sagara; Kazuhiko Shibata; Hiromu Kawasaki; Toshiaki Sendo; Yutaka Gomita

doi:10.1254/jphs.FP0072150

Full Papers

Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

Yoshihisa Kitamura, Kouhei Kitagawa, Shizue Kimoto, Hidenori Sagara, Kazuhiko Shibata, Hiromu Kawasaki, Toshiaki Sendo, Yutaka Gomita

Author information

Yoshihisa Kitamura
Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan
Kouhei Kitagawa
Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan
Department of Hospital Pharmacy, Okayama University Medical School, Japan
Shizue Kimoto
Department of Hospital Pharmacy, Okayama University Medical School, Japan
Hidenori Sagara
Department of Hospital Pharmacy, Okayama University Medical School, Japan
Kazuhiko Shibata
Department of Hospital Pharmacy, Okayama University Medical School, Japan
Hiromu Kawasaki
Department of Clinical Pharmaceutical Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan
Toshiaki Sendo
Department of Hospital Pharmacy, Okayama University Medical School, Japan
Yutaka Gomita
Department of Hospital Pharmacy, Okayama University Medical School, Japan

Keywords: selegiline, monoamine oxidase-B, treatment-resistance depression, forced swim test, dopamine D₃ receptor

JOURNAL FREE ACCESS

2008 Volume 106 Issue 4 Pages 639-644

DOI https://doi.org/10.1254/jphs.FP0072150

View "Advance Publication" version (April 9, 2008).

Details

Abstract

In the present study, we investigated the effect of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test after the administration of selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor. Single and repeated administration of selegiline significantly decreased the duration of immobility in normal rats. When selegiline was administered for 15 days, we observed a significant decrease in immobility in rats treated with ACTH for 14 days. The immobility-decreasing effect of selegiline was blocked by nafadotride, a selective dopamine D₃–receptor antagonist in normal and ACTH-treated rats. Selegiline may be useful in an animal model of depressive conditions resistant to tricyclic antidepressant treatment via the dopamine D₃ receptor.

Corresponding author

Register with J-STAGE for free!